Genmab A/S
GMAB
Xếp hạng trong cổ phiếu
#977
Genmab A/S, a biotechnology firm based in Copenhagen, Denmark, specializes in... Genmab A/S, a biotechnology firm based in Copenhagen, Denmark, specializes in the discovery and development of innovative antibody-based treatments for various forms of cancer and other serious conditions. The company currently commercializes several key therapeutic antibodies. DARZALEX (daratumumab) is utilized in the treatment of multiple myeloma (MM), specific non-MM blood cancers, and AL amyloidosis. Other marketed offerings include teprotumumab for thyroid eye disease, ofatumumab, which addresses chronic lymphocytic leukemia (CLL) and multiple sclerosis, and Amivantamab for advanced or metastatic non-small cell lung cancer (NSCLC) as well as gastric or esophageal cancers. Genmab maintains an extensive and active development pipeline, featuring a broad range of experimental therapies. This includes GEN1047, tisotumab vedotin (targeting cervical, ovarian, and other solid cancers), and bispecific antibodies such as DuoBody-PD-L1x4-1BB and DuoBody-CD40x4-1BB, which are engineered for solid tumors. Epcoritamab is being developed for relapsed/refractory diffuse large B-cell lymphoma and CLL, while HexaBody-CD38 and DuoHexaBody-CD37 are designed to treat hematological malignancies. Further assets in the pipeline encompass Teclistamab, currently in Phase 2 clinical trials for vaso-occlusive crises, Camidanlumab tesirine for Hodgkin lymphoma and solid tumors, JNJ-64007957 and JNJ-64407564 for MM, PRV-015 for celiac disease, Mim8 for haemophilia A, and Lu AF82422 for multiple system atrophy. Additionally, the company is engaged in approximately 20 pre-clinical research programs. Strategic collaborations are a cornerstone of Genmab's operational model. It holds a commercial license and co-development agreement with Seagen Inc. for tisotumab vedotin. The company also partners with CureVac AG on the research and development of mRNA-based antibody products, with argenx for the discovery of novel therapeutic antibodies in immunology and oncology, and with AbbVie for the development of epcoritamab. Other notable collaborators include BioNTech, Janssen, Novo Nordisk A/S, BliNK Biomedical SAS, and Bolt Biotherapeutics, Inc. Genmab A/S was established in 1999 and is headquartered in Copenhagen, Denmark.
Giá cổ phiếu
$398.84
Đồng bộ lần cuối: 2026-10-16
Vốn hóa thị trường
$24.52B
Thay đổi (1 ngày)
-0.55%
Thay đổi (1 năm)
20.13%
Quốc gia
DK
Giao dịch Genmab A/S (GMAB)
Danh mục
Healthcare
EPS của Genmab A/S (GMAB)
EPS tính đến 2026 TTM: 0
Theo các báo cáo tài chính mới nhất và giá cổ phiếu của Genmab A/S, EPS hiện tại của công ty (TTM) là 0. Vào cuối năm 2026, công ty có EPS là 0, bằng với EPS năm 2026 là 0.
Lịch sử EPS của Genmab A/S từ 2026 đến 2026
EPS vào cuối mỗi năm
| Năm | EPS | Thay đổi |
|---|---|---|
| Không đủ dữ liệu cho ngày được cung cấp. | ||
EPS cho các công ty hoặc đối thủ cạnh tranh tương tự
| Công ty | EPS | Chênh lệch EPS | Quốc gia |
|---|---|---|---|
| $17.32 | - |
US
|
|
| $-7.98 | - |
US
|
|
| $-5.29 | - |
AU
|
|
| - | - |
CH
|
|
| $27.74 | - |
NL
|
